Lower urinary tract symptom prevalence and management among patients with multiple sclerosis - Wikidata - wikimedia - TriplyDB

Lower urinary tract symptom prevalence and management among patients with multiple sclerosis

Lower urinary tract symptom prevalence and management among patients with multiple sclerosis

http://www.wikidata.org/entity/Q35114665

about

Recent advances in the understanding of male lower urinary tract symptoms (LUTS)Autonomic Dysregulation in Multiple Sclerosis Secondary and tertiary treatments for multiple sclerosis patients with urinary symptoms Management of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity.A conceptual model of the risk of elder abuse posed by incontinence and care dependence.Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS

P2860

Q26748557-4347E70E-B2F4-4CBC-BFD3-6E1BF3100CB8 Q26799341-5D2BBD8C-590F-41AC-9E52-0E31130E7D90 Q28070040-F4D38BBC-41E2-465F-A048-50FADF188FF4 Q38508246-5AAFED59-BF9A-4F83-85AC-8942CC6B8CFB Q41110077-ECBA630B-2E14-4718-A26F-7737E4C87FBC Q47280523-D5F11B6D-BAC5-4AE9-A9D1-27FDEE31E495 Q58780881-683016E4-65C7-4C4A-9A7E-AF7239D9B00D

P2860

Lower urinary tract symptom prevalence and management among patients with multiple sclerosis

http://www.wikidata.org/entity/Q35114665

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Lower urinary tract symptom pr ...... tients with multiple sclerosis

@ast

Lower urinary tract symptom pr ...... tients with multiple sclerosis

@en

type

label

Lower urinary tract symptom pr ...... tients with multiple sclerosis

@ast

Lower urinary tract symptom pr ...... tients with multiple sclerosis

@en

prefLabel

Lower urinary tract symptom pr ...... tients with multiple sclerosis

@ast

Lower urinary tract symptom pr ...... tients with multiple sclerosis

@en

P1433

Q35114665-AAB0E2D8-F18B-4324-948F-013A685B49D8

P1476

Q35114665-3EBA6AB1-ED43-4727-934E-5859D8A3176E

P2093

Q35114665-36C18B6D-51CC-4A60-9593-0B9874BDC91D

Q35114665-521AED85-5A56-4EE0-B0D7-9F63725AEDE6

Q35114665-804E27F4-B822-4E57-A84D-31AEB37B0B93

Q35114665-8297EE61-DF89-441A-853B-D8A3A94DD052

Q35114665-90048BBE-F1EE-4B5F-9240-A4C92156792D

Q35114665-99F8C91C-3C23-409A-9774-64118C142038

P2860

Q35114665-00E43890-0A88-4923-814A-929642E3E190

Q35114665-055B1D24-09B1-4E1B-B24B-AD13CB0A0AED

Q35114665-16C54280-01EA-4EA1-87C2-09C2E3772CF0

Q35114665-2D9F8DBE-D795-4579-8FB5-E9C28228E952

Q35114665-3AFF0025-35D5-41A2-8664-2012CB13011B

Q35114665-3D2AB414-E05D-4473-88C1-E6552A9225CF

Q35114665-4470D833-203F-49DD-A63E-AF2C41E6C730

Q35114665-47054503-3CFA-4856-AA8E-C7F89B494AE0

Q35114665-4D74788F-0EDC-4DBE-80BE-E78DBF940201

Q35114665-51804358-EE6C-45A2-A271-4AC4B524A9E0

P304

Q35114665-8899756A-97AD-494D-B2D4-3AABB5CC3CC2

P31

Q35114665-66D8E4BB-356A-42E2-AF76-790EDCB3BF4E

P356

Q35114665-01B9CDC5-727A-415D-B2D3-671C651622C4

P433

Q35114665-EC7A47E8-F3EA-4C07-AA4E-EC5E8B33FD77

P478

Q35114665-2B6945E1-D7AF-4ED8-8647-3E33E8BA211B

P577

Q35114665-02F14C38-BB3F-4967-88FE-FFCF43D61224

P698

Q35114665-1A9C3819-FFFB-46DE-8768-F21E92BB796F

P921

Q35114665-ADE7B1FE-BA63-4E27-9101-5BD3859198C9

P932

Q35114665-04D3A353-092B-4B15-81CD-139547829658

P356

1537-2073.2013-040

P1433

International journal of MS care

P1476

Lower urinary tract symptom pr ...... tients with multiple sclerosis

@en

P2093

Daniel C Malone

http://www.w3.org/2001/XMLSchema#string

Denise R Globe

http://www.w3.org/2001/XMLSchema#string

Edward P Armstrong

http://www.w3.org/2001/XMLSchema#string

Jack Burks

http://www.w3.org/2001/XMLSchema#string

Karin S Coyne

http://www.w3.org/2001/XMLSchema#string

Kristin M Khalaf

http://www.w3.org/2001/XMLSchema#string

P2860

The prevalence of multiple sclerosis in 3 US communities

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life.

Bladder dysfunction in multiple sclerosis.

Challenges for managing overactive bladder and guidance for patient support.

Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression.

Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry.

The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study.

Assessing patients' descriptions of lower urinary tract symptoms (LUTS) and perspectives on treatment outcomes: results of qualitative research.

Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group.

P304

14-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7224/1537-2073.2013-040

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25741223

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

4338639

http://www.w3.org/2001/XMLSchema#string